References

Aning JJ, Horsnell J, Gilbert HW, Kinder RB. Management of acute urinary retention. Br J Hosp Med.. 2007; 68:(8)408-411 https://doi.org/10.12968/hmed.2007.68.8.24491

Cathcart P, van der Meulen J, Armitage J, Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol.. 2006; 176:(1)200-204 https://doi.org/10.1016/S0022-5347(06)00509-X

Fisher E, Subramonian K, Omar MI. The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database Syst Rev.. 2014; (6) https://doi.org/10.1002/14651858.CD006744.pub3

Fitzpatrick JM, Kirby RS. Management of acute urinary retention. BJU Int.. 2006; 97:16-22 https://doi.org/10.1111/j.1464-410X.2006.06100.x

García-Perdomo HA, Lopez HE, Tacklind J. 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev.. 2015; (11) https://doi.org/10.1002/14651858.CD011928

EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2021. https://tinyurl.com/yebsawdb (accessed 26 April 2021)

Halbgewachs C, Domes T. Postobstructive diuresis: pay close attention to urinary retention. Can Fam Physician.. 2015; 61:(2)137-142

Hollingsworth JM, Wei JT. Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy?. Curr Opin Urol.. 2010; 20:(1)1-6 https://doi.org/10.1097/MOU.0b013e3283336f96

Joint Formulary Committee. Urinary retention. 2021. https://bnf.nice.org.uk/treatment-summary/urinary-retention.html (accessed 26 April 2021)

Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum). Drug Safety Update. 2019. https://tinyurl.com/2steuehj (accessed 26 April 2021)

National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE guideline NG131. 2019. https://www.nice.org.uk/guidance/ng131 (accessed 26 April 2021)

National Institute for Health and Care Excellence. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. Medical technologies guidance MTG49. 2020. https://www.nice.org.uk/guidance/MTG49 (accessed 26 April 2021)

Nazarko L. Trial without catheter in community settings. Independent Nurse.. 2020; 11:18-22 https://doi.org/10.12968/indn.2020.11.18

NHS Borders. Appendix 1: protocol for males with acute retention of urine (algorithm). 2019. http://www.nhsborders.scot.nhs.uk/media/386164/final-catheterisation-policy-september-2019-2.pdf (accessed 26 April 2021)

SOAP notes. 2021. https://www.ncbi.nlm.nih.gov/books/NBK482263/ (accessed 26 April 2021)

Roehrborn CG. Acute urinary retention: risks and management. Rev Urol.. 2005; 7:S31-S41

Royal College of Nursing. Catheter care. RCN guidance for health care professionals. 2019. https://www.rcn.org.uk/professional-development/publications/pub-007313 (accessed 26 April 2021)

Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician.. 2008; 77:(5)643-650

Serlin DC, Heidelbaugh JJ, Stoffel JT. Urinary retention in adults: evaluation and initial management. Am Fam Physician.. 2018; 98:(8)496-503

Thomas K, Chow K, Kirby RS. Acute Urinary Retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis.. 2004; 7:(1)32-37 https://doi.org/10.1038/sj.pcan.4500700

Verhamme KMC, Dieleman JP, Van Wijk MAM, van der Lei J, Bosch JLHR, Stricker BHC, Sturkenboom MCJM. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med.. 2005; 165:(13)1547-1551 https://doi.org/10.1001/archinte.165.13.1547

Verhamme KMC, Sturkenboom MCJM, Stricker BHC, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf.. 2008; 31:(5)373-388 https://doi.org/10.2165/00002018-200831050-00002

Yoon PD, Chalasani V, Woo HH. Systematic review and meta-analysis on management of acute urinary retention. Prostate Cancer Prostatic Dis.. 2015; 18:(4)297-302 https://doi.org/10.1038/pcan.2015.15

Acute urinary retention: patient investigations and treatments

13 May 2021
Volume 30 · Issue 9

Abstract

Acute urinary retention (AUR) is the sudden inability to pass urine. AUR is more common in men and older men are at highest risk. The most common causes are obstructive in nature—prostatic hyperplasia is responsible for more than half the cases of AUR in men. AUR can also be caused by infection, inflammation, and by iatrogenic and neurological problems. This article outlines how AUR is diagnosed and treated.

Urinary retention is the inability to voluntarily urinate. Acute urinary retention (AUR) is a medical emergency characterised by the abrupt development of the inability to pass urine over a period of hours (Joint Formulary Committee, 2021). AUR may occur due to urethral blockage, drug treatment (such as use of antimuscarinic drugs, sympathomimetics or tricyclic antidepressants), conditions that reduce detrusor contractions or interfere with relaxation of the urethra, and neurogenic causes. It may also occur postpartum or postoperatively.

Men are more likely to suffer AUR than women. There is a lack of recent studies. Past research indicates that 86% of hospital admissions for AUR involve men and 14% women. Older men are at greater risk of AUR and around 10% of men aged 70–75 will experience an episode of AUR (Cathcart et al, 2006). In the UK, more than 30 000 people are admitted annually with AUR and greater numbers attend emergency departments (Aning et al, 2007).

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content